Compare DexCom, Inc. (DXCM) vs Microsoft (MSFT) Price & Performance

DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.

The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.

Microsoft (MSFT) trades at $405.34, up 5.3% in the past 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q1 2026 EPS of $4.27 exceeding the $4.06 forecast. Revenue grew to $281.72 billion in 2025, and net income reached $101.83 billion. Analyst sentiment is overwhelmingly positive, with 80.49% recommending Buy and a consensus price target of $547.23.

The outlook for MSFT remains favorable due to robust AI-driven growth in Azure and Copilot, though rising capital expenditures and competitive pressures pose risks. The stock offers upside potential based on earnings momentum and institutional support, but investors should monitor execution on AI investments and macroeconomic conditions affecting tech valuations.